Dr Tasian is a pediatric oncologist and physician-scientist who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. She specializes in the clinical care of children with leukemia and lymphoma, is an internationally-recognized expert in pediatric ALL and AML, and serves as the Chief of the Hematologic Malignancies Program at CHOP. Her bench-to-bedside and bedside-back-to-bench translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML. Dr Tasian has leadership roles in the Children’s Oncology Group (COG) ALL and Myeloid Diseases committees and LLS PedAL/EuPAL consortium, is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or international early phase clinical trials testing precision medicine therapies in children with high-risk leukemias.